Insurance Coverage for Emerging Diabetes Technologies: Payers' Perspective

Advances in glucose monitoring and insulin delivery technologies have led to the development of innovative self-management tools, such as continuous glucose monitoring, automated insulin delivery systems, and smart connected insulin pens. Although the clinical advantages of today's emerging dia...

Full description

Saved in:
Bibliographic Details
Published inDiabetes technology & therapeutics Vol. 23; no. S3; p. S28
Main Authors Nolan, Tim, Frazzitta, Marie
Format Journal Article
LanguageEnglish
Published United States 01.09.2021
Subjects
Online AccessGet full text
ISSN1520-9156
1557-8593
1557-8593
DOI10.1089/dia.2021.0262

Cover

Abstract Advances in glucose monitoring and insulin delivery technologies have led to the development of innovative self-management tools, such as continuous glucose monitoring, automated insulin delivery systems, and smart connected insulin pens. Although the clinical advantages of today's emerging diabetes technologies are well documented, the cost of integrating these tools into clinical practice must be considered to sustain the financial viability of both public and private insurers. Most clinicians are unfamiliar with the process the commercial insurers follow when making these decisions. This article reviews the key factors the insurers consider when determining eligibility criteria.
AbstractList Advances in glucose monitoring and insulin delivery technologies have led to the development of innovative self-management tools, such as continuous glucose monitoring, automated insulin delivery systems, and smart connected insulin pens. Although the clinical advantages of today's emerging diabetes technologies are well documented, the cost of integrating these tools into clinical practice must be considered to sustain the financial viability of both public and private insurers. Most clinicians are unfamiliar with the process the commercial insurers follow when making these decisions. This article reviews the key factors the insurers consider when determining eligibility criteria.
Author Nolan, Tim
Frazzitta, Marie
Author_xml – sequence: 1
  givenname: Tim
  surname: Nolan
  fullname: Nolan, Tim
  organization: TEN Healthcare Strategies, Newtown, Pennsylvania, USA
– sequence: 2
  givenname: Marie
  surname: Frazzitta
  fullname: Frazzitta, Marie
  organization: Abbott Diabetes Care, Department of Medical Affairs, Alameda, California, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34546078$$D View this record in MEDLINE/PubMed
BookMark eNo90D1PwzAQBmALgegHjKzIG1OCP2ObDZUCRZXoUObIsS8hKE0iuy3qv6dRgeXuhve94Zmg87ZrAaEbSlJKtLn3tU0ZYTQlLGNnaEylVImWhp8PNyOJoTIboUmMX4QQxRm9RCMupMiI0mP0tmjjLtjWAZ51ewi2Alx2Ac83EKq6rfBTbQvYQsRrcJ9t13RVDfEBr-wBQrzDq-PswW3rPVyhi9I2Ea5_9xR9PM_Xs9dk-f6ymD0uE8eN3CbKk5Ipp7wpS02NKKn1kgsNAoh0RnlpS-JB-UK7zHlTFEx4zZ3UxlErPJ-i9PR31_b28G2bJu9DvbHhkFOSDyj5ESUfUPIB5Vi4PRX6XbEB_5_-U-A_yMZgLg
CitedBy_id crossref_primary_10_1177_19322968241274796
crossref_primary_10_1111_dom_15087
crossref_primary_10_1089_dia_2021_0271
crossref_primary_10_4103_cdrp_cdrp_16_24
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
ADTOC
UNPAY
DOI 10.1089/dia.2021.0262
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1557-8593
ExternalDocumentID 10.1089/dia.2021.0262
34546078
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GroupedDBID ---
0R~
29F
34G
39C
4.4
53G
6PF
AAWTL
ABBKN
ABJNI
ACGFS
ADBBV
AENEX
AHMBA
ALMA_UNASSIGNED_HOLDINGS
BNQNF
CAG
CGR
COF
CS3
CUY
CVF
DU5
EBS
ECM
EIF
EJD
F5P
IAO
IER
IHR
IM4
INH
INR
ITC
MV1
NPM
NQHIM
O9-
PQQKQ
RIG
RML
UE5
ADTOC
SCNPE
UNPAY
ID FETCH-LOGICAL-c395t-7d0f27c7d9ff8194f1ad5348e4e05c97d5af0de7db8c6cd9bb24d83c589c1a4d3
IEDL.DBID UNPAY
ISSN 1520-9156
1557-8593
IngestDate Sun Sep 07 10:54:13 EDT 2025
Thu Jan 02 22:55:42 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue S3
Keywords Continuous glucose monitoring
Diabetes
Cost
Insurance
Risk stratification
Language English
License cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c395t-7d0f27c7d9ff8194f1ad5348e4e05c97d5af0de7db8c6cd9bb24d83c589c1a4d3
OpenAccessLink https://proxy.k.utb.cz/login?url=https://doi.org/10.1089/dia.2021.0262
PMID 34546078
ParticipantIDs unpaywall_primary_10_1089_dia_2021_0262
pubmed_primary_34546078
PublicationCentury 2000
PublicationDate 2021-09-00
PublicationDateYYYYMMDD 2021-09-01
PublicationDate_xml – month: 09
  year: 2021
  text: 2021-09-00
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Diabetes technology & therapeutics
PublicationTitleAlternate Diabetes Technol Ther
PublicationYear 2021
SSID ssj0007321
Score 2.3204331
SecondaryResourceType review_article
Snippet Advances in glucose monitoring and insulin delivery technologies have led to the development of innovative self-management tools, such as continuous glucose...
SourceID unpaywall
pubmed
SourceType Open Access Repository
Index Database
StartPage S28
SubjectTerms Blood Glucose
Blood Glucose Self-Monitoring
Diabetes Mellitus - therapy
Humans
Insulin Infusion Systems
Insurance Coverage
Title Insurance Coverage for Emerging Diabetes Technologies: Payers' Perspective
URI https://www.ncbi.nlm.nih.gov/pubmed/34546078
https://doi.org/10.1089/dia.2021.0262
UnpaywallVersion publishedVersion
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1NS8NAEF20BT35_VHRsgehp9Sku5tkvZViqYWWHCzUU9jPiyUWmyD6651NYq160HM2sDyWmTc7s-8hdE0g5CtfEs9aZTzas9oDUh97kmoTEhkAZygHZKfhaEbHczavh2jcW5hv_fuY3wBIUMT1nLCmi7TNkAHlbqDmbJr0H0stVCh_eFC6tEJqhIjLOKm1NH_9v5FldotsKd5exWKxkU6G-2j4uZFqiuSpW-Syq95_aDT-udMDtFcTStyvTsAh2jLZEdqZ1C3zYzS-z1aFc88weODGNSF-YCCq2N1GOYMiXM_ErPD6lh2K51ucCEfGOzj5eo15gmbDu4fByKsNFDxFOMu9SPu2F6lIc2sh81MbCM0IjQ01PlM80kxYX5tIy1iFSnMpe1THRLGYq0BQTU5RI3vOzDnCsYR10jLfCida7wyOCBTPWghjOPN1C51V0KbLSiUjJZTREAhIC3XWWK8_lq3vmKcAWupASx1oF_9eeYka-UthroAP5LKNtqfJpF2fiQ-rxLKP
linkProvider Unpaywall
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1NS8NAEF2kBT35_VFR2YPQU2qS3U12vRWx1IKlBwv1FPbzYonFJoj-emeTWKse9JwNLI9l5s3O7HsIXRII-TpUJHBO24DGzgRA6nmgqLEJURFwhmpAdpwMp3Q0Y7NmiMa_hfnWv-fiCkCCIi72wpo-0rYTBpS7hdrT8aT_WGmhQvkjosqlFVIjRFwmSKOl-ev_tSyzVeYL-fYq5_O1dDLYQYPPjdRTJE-9slA9_f5Do_HPne6i7YZQ4n59AvbQhs330eZ90zI_QKO7fFl69wyLb_y4JsQPDEQV-9sob1CEm5mYJV7dskPxfI0n0pPxLp58vcY8RNPB7cPNMGgMFAJNBCuC1IQuTnVqhHOQ-amLpGGEckttyLRIDZMuNDY1iutEG6FUTA0nmnGhI0kNOUKt_Dm3JwhzBeuUY6GTXrTeGxwRKJ6NlNYKFpoOOq6hzRa1SkZGKKMJEJAO6q6wXn2sWt9cZABa5kHLPGin_155hlrFS2nPgQ8U6qI5DR-Bn7GD
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Insurance+Coverage+for+Emerging+Diabetes+Technologies%3A+Payers%27+Perspective&rft.jtitle=Diabetes+technology+%26+therapeutics&rft.issn=1520-9156&rft_id=info:doi/10.1089%2Fdia.2021.0262&rft.externalDocID=10.1089%2Fdia.2021.0262
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1520-9156&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1520-9156&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1520-9156&client=summon